

ASX ANNOUNCEMENT
9 February 2021



CLEANSING NOTICE

NOTICE PURSUANT TO PARAGRAPH 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“Act”).

The Company advises that on 8 February 2021 it issued 3,000,000 fully paid ordinary shares upon exercise of options and 1,121,052 fully paid ordinary shares to employees & consultants of the Company.

LGP gives notice that:

1. the Shares were issued without disclosure under Part 6D.2 of the Corporations Act;
2. as at the date of this notice the Company has complied with:
 - i. the provision of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. section 674 of the Corporations Act; and
3. as at the date of this notice there is no excluded information required to be disclosed under section 708A(6)(e) of the Corporations Act.

Notwithstanding this, the Company continues to progress towards the launch of the large-scale medical cannabis study referred to in the September and December 2020 Quarterly Activities Reports.

In accordance with paragraph 7(f) of ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547, this notice also serves as a cleansing notice for the securities purchase plan of the Company.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in blue ink, appearing to read "Alistair Warren", is written over a horizontal line.

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren, Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
T: +61 8 6280 0050

Fleta Solomon, Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

